Format

Send to

Choose Destination
Int J Mol Sci. 2017 Jun 8;18(6). pii: E1234. doi: 10.3390/ijms18061234.

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.

Huang TT1,2, Su JC3,4, Liu CY5,6,7, Shiau CW8, Chen KF9,10.

Author information

1
Comprehensive Breast Health Center, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. abby-eve@hotmail.com.
2
Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. abby-eve@hotmail.com.
3
Institute of Biopharmaceutical Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan. jjjaannee@hotmail.com.
4
Faculty of Pharmacy, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan. jjjaannee@hotmail.com.
5
Comprehensive Breast Health Center, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. cyliu3@gmail.com.
6
Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan. cyliu3@gmail.com.
7
School of Medicine, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan. cyliu3@gmail.com.
8
Institute of Biopharmaceutical Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan. cwshiau@ym.edu.tw.
9
Department of Medical Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. kfchen1970@ntu.edu.tw.
10
National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. kfchen1970@ntu.edu.tw.

Abstract

The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 1 (SHP-1), a non-receptor protein tyrosine phosphatase, has been reported as a negative regulator of phosphorylated signal transducer and activator of transcription 3 (STAT3) and linked to tumor development. In this present review, we will discuss the importance and function of SHP-1/p-STAT3 signaling in nonmalignant conditions as well as malignancies, its cross-talk with other pathways, the current clinical development and the potential role of inhibitors of this pathway in anticancer therapy and clinical relevance of SHP-1/p-STAT3 in cancers. Lastly, we will summarize and highlight work involving novel drugs/compounds targeting SHP-1/p-STAT3 signaling and combined strategies that were/are discovered in our and our colleagues' laboratories.

KEYWORDS:

SHP-1 (SH2 domain-containing protein tyrosine phosphatase-1); STAT3 (signal transducer and activator of transcription 3); cancer therapy

PMID:
28594363
PMCID:
PMC5486057
DOI:
10.3390/ijms18061234
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center